Gastroenteropancreatic neuroendocrine tumours: an overview

British Journal of Nursing : BJN
Louise Davies, Martin O Weickert

Abstract

Gastroenteropancreatic neuroendocrine tumours (GEP-NET) represent a heterogeneous family of diseases of often challenging clinical management. Although many GEP-NET are slow progressing and frequently less aggressive than neoplasms of other origin, they can metastasise and reduce the life span of the patient. GEP-NET can be functioning (secreting hormones that may cause symptoms and organ damage), but some 60% are non-functioning. Thorough clinical assessment including family history, biochemical tests, radiology and nuclear medicine scans, and histological confirmation are important to tailor the optimal treatment of GEP-NET, which should be managed with a multidisciplinary approach and mainly guided by tumour grading and staging, functioning status, and location of the primary lesion.

References

Sep 13, 2006·Virchows Archiv : an International Journal of Pathology·G RindiUNKNOWN European Neuroendocrine Tumor Society (ENETS)
Feb 22, 2007·Neuroendocrinology·Massimo FalconiUNKNOWN European Neuroendocrine Tumor Society
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Davide CampanaPaola Tomassetti
Oct 18, 2007·Neuroendocrinology·Hakan AhlmanUNKNOWN Frascati Consensus Conference participants
Oct 15, 2008·Cancer·Oyvind HausoIrvin M Modlin
Jul 29, 2010·Pancreas·Aaron I VinikUNKNOWN North American Neuroendocrine Tumor Society (NANETS)
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Nov 5, 2011·Gut·John K RamageUNKNOWN UK and Ireland Neuroendocrine Tumour Society
Apr 16, 2013·Best Practice & Research. Clinical Gastroenterology·Paola CapelliAldo Scarpa
Apr 29, 2014·Endocrine Pathology·Giuseppe PelosiAldo Scarpa
Jul 12, 2014·The New England Journal of Medicine·Martyn E CaplinUNKNOWN CLARINET Investigators
Sep 16, 2015·The Lancet Oncology·Kjell ObergJames Goldenring
Dec 9, 2015·Critical Reviews in Oncology/hematology·Rossana BerardiStefano Cascinu
Jan 6, 2016·Neuroendocrinology·U-F PapeUNKNOWN Vienna Consensus Conference participants

❮ Previous
Next ❯

Software Mentioned

NET
GEP

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

© 2022 Meta ULC. All rights reserved